Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.356
+0.004 (0.99%)
At close: Jan 17, 2025, 4:00 PM
0.347
-0.009 (-2.56%)
Pre-market: Jan 21, 2025, 8:19 AM EST
Cyclacel Pharmaceuticals Revenue
Cyclacel Pharmaceuticals had revenue of $10.00K in the quarter ending September 30, 2024, a decrease of -37.50%. This brings the company's revenue in the last twelve months to $74.00K, down -80.98% year-over-year. In the year 2023, Cyclacel Pharmaceuticals had annual revenue of $420.00K.
Revenue (ttm)
$74.00K
Revenue Growth
-80.98%
P/S Ratio
10.35
Revenue / Employee
$6,167
Employees
12
Market Cap
2.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
CYCC News
- 17 days ago - Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 6 weeks ago - Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 3 months ago - Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire